Format

Send to

Choose Destination
Vaccine. 2014 Oct 14;32(45):5889-92. doi: 10.1016/j.vaccine.2014.08.073. Epub 2014 Sep 13.

Novel vector vaccine against Brucella abortus based on influenza A viruses expressing Brucella L7/L12 or Omp16 proteins: evaluation of protection in pregnant heifers.

Author information

1
The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409 Gvardeisky, Kazakhstan. Electronic address: tabynov_81@mail.ru.
2
The Research Institute for Biological Safety Problems, Zhambulskaya oblast, Kordaiskiy rayon, 080409 Gvardeisky, Kazakhstan.

Abstract

The present study provides the first information about the protection of a novel influenza viral vector vaccine expressing the Brucella proteins ribosomal L7/L12 or Omp16 containing the adjuvant Montanide Gel01 in pregnant heifers. Immunization of pregnant heifers was conducted via the conjunctival (n=10) or subcutaneous (n=10) route using cross prime and booster vaccination schedules at an interval of 28 days. The vector vaccine was evaluated in comparison with positive control groups vaccinated with Brucella abortus S19 (n=10) or B. abortus RB51 (n=10) and a negative (PBS+Montanide Gel01; n=10) control group. Via both the conjunctival or subcutaneous route, evaluation of protectiveness against abortion, effectiveness of vaccination and index of infection (in heifers and their fetuses or calves) demonstrated the vector vaccine provided good protection against B. abortus 544 infection compared to the negative control group (PBS+Montanide Gel01) and comparable protection to commercial vaccines B. abortus S19 or B. abortus RB51.

KEYWORDS:

Brucella abortus; Influenza viral vector; Pregnant heifer; Protection; Vaccine

PMID:
25218295
DOI:
10.1016/j.vaccine.2014.08.073
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center